与二甲双胍或磺脲类药物相比，2型糖尿病的胰岛素治疗会使全因死亡率增加约一倍，并增加癌症、肾脏和心血管事件，且存在剂量-反应关系（每天每公斤体重每多用1 IU，死亡率增加54%）。
原始表述
ودراسة Currie الواسعة على 84,622 مريضًا وجدت أن الأنسولين منفردًا ضاعف الوفيات تقريبًا (HR 2.20) ورفع السرطان والفشل الكلوي مقارنةً بالميتفورمين. وأكدت دراسة Holden علاقة الجرعة بالوفاة: كل وحدة إضافية ترفع الوفيات 54%.
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
与二甲双胍或磺脲类药物相比，2型糖尿病的胰岛素治疗会使全因死亡率增加约一倍，并增加癌症、肾脏和心血管事件，且存在剂量-反应关系（每天每公斤体重每多用1 IU，死亡率增加54%）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (not Elawady)
- 出处
- https://eltayebat.com/rule/insulin-injections/
- 归属的不确定性
- Editorial narrative and study selection written by the archive operators.
- 所声称的机制
Exogenous insulin (hyperinsulinaemia) directly causes mortality, cancer and vascular disease.
- 所声称的健康影响
Death, cancer, MI, stroke, renal failure
- 涉及人群
Type 2 diabetes
- Elawady 设定的地域限制
none found
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Insulin itself doubles mortality and raises cancer and complications in a dose-dependent way.
2. 哪些内容可证实是正确的？
The figures are quoted correctly as associations: insulin monotherapy vs metformin aHR 2.197 for death, 1.437 for cancer (A-INS-08; this study did not analyse insulin dose); per 1-unit increase in IU/kg/day aHR 1.54 for death (A-INS-10); adding insulin vs sulfonylurea to metformin aHR 1.30 for the composite and 1.44 for death (A-INS-13); insulin use and cancer mortality HR 1.9 (A-INS-11) with a gradient by number of pharmacy dispensations (A-INS-12; cancer mortality only, called preliminary by its authors); insulin-based regimens vs combination oral agents HR 1.49 (A-INS-09).
3. 哪些内容是错误或夸大的？
All of these are retrospective observational studies. In Currie et al. insulin users differed sharply at baseline (diabetes duration 5.2 vs 1.5 years; creatinine >130 umol/L in 21.1% vs 2.2%), follow-up was censored at regimen switch, and bias is judged critical; the study cannot support a causal 'doubling' or the dose-response element (A-INS-08). In Bowker et al. the 'dose' was the number of dispensations counted in the same window as death, which invites reverse causation (A-INS-12). Holden et al. state the association should be tested in interventional studies (A-INS-10); Bowker et al. state it is uncertain whether the risk reflects harm from insulin, protection by metformin, or unmeasured factors (A-INS-11); Roumie et al. call for further investigation (A-INS-13). Patients receive insulin, and higher doses, because their disease is more advanced and they are more insulin resistant, obese or ill (confounding by indication; reverse causation). A meta-analysis of 20 RCTs found no mortality effect of insulin (RR 0.99, 0.92-1.06), but more severe hypoglycaemia (RR 1.70) (I-INS-122). In the randomised ORIGIN trial, glargine had neutral effects on cardiovascular outcomes (HR 1.02) and cancers (HR 1.00) over 6.2 years (A-INS-07, I-INS-05), and in UKPDS insulin-based intensive therapy reduced microvascular complications without excess macrovascular disease (A-INS-16) and was associated with fewer deaths at 10 years (I-INS-02).
4. 哪些内容仍不明确？
RCT evidence in very insulin-resistant, high-dose, late-stage type 2 diabetes is limited; whether high insulin doses carry some independent risk cannot be excluded.
5. 哪些研究支持该说法？
A-INS-08, A-INS-09, A-INS-10, A-INS-11, A-INS-12, A-INS-13 (associations only; the IU/kg/day dose-response comes from A-INS-10 alone).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
观察性研究中的信号，是指南在2型糖尿病中优先推荐二甲双胍和具有心肾保护作用的药物、并避免不必要地升级胰岛素治疗的理由之一。但这些信号并不能说明胰岛素会致命，也不能成为在需要胰岛素时停用它的理由。
评估详情
- 证据确定性的依据
The numbers are correctly reported from observational cohorts, but these are strongly confounded by indication (sicker patients with longer disease and failure of tablets receive insulin; doses rise with insulin resistance and illness); the authors themselves call for interventional studies. A meta-analysis of 20 RCTs (18,599 patients) found no effect of insulin on all-cause mortality (RR 0.99, 0.92-1.06) or cardiovascular mortality (RR 0.99) versus other drugs (I-INS-122), and ORIGIN and UKPDS found no increase in mortality, cardiovascular events or cancer. Certainty raised from low to moderate because randomised evidence directly excludes a doubling of mortality; it is not high because late-stage, high-dose users are under-represented in RCTs.
- 来源质量
Archive editorial quoting retrospective database cohorts.
- 地区可推广性
UK, Canadian and US data; transferable as associations.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Does insulin therapy in type 2 diabetes cause about a doubling of mortality and more cancer, renal and cardiovascular events, dose-dependently, compared with metformin or sulfonylureas?
研究问题详解 (PICO)
- 人群
- Adults with type 2 diabetes
- 干预或暴露
- Insulin therapy (and dose)
- 对照
- Metformin, sulfonylureas or other drugs
- 地域范围
- universal biology
- 结局指标
- All-cause mortality
- Cancer
- CV events
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
UK database: insulin users vs metformin users
Currie CJ et al.. J Clin Endocrinol Metab 2013 · PMID 23372169 · DOI 10.1210/jc.2012-3042 队列研究全文，含结构化偏倚风险评估UK database cohort (Currie): insulin monotherapy vs metformin.
- 实际结果
- aHR 2.197 for death.
- 方法学质量
- low (retrospective, confounding by indication)
- 相关性
- direct question, biased design
- 局限
- Sicker patients receive insulin.
Higher insulin doses and outcomes
Dose association (Holden).
- 实际结果
- aHR 1.54 per 1 IU/kg/day.
- 方法学质量
- low
- 相关性
- direct, biased design
- 局限
- Reverse causation.
Second drug after metformin: insulin or sulfonylurea
Insulin vs sulfonylurea added to metformin (Roumie).
- 实际结果
- aHR 1.44 for death.
- 方法学质量
- low-moderate (propensity-matched cohort)
- 相关性
- direct
- 局限
- Residual confounding.
哪些证据不支持该说法？
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z Meta分析已核查摘要新增Meta-analysis of 20 RCTs, 18,599 patients.
- 实际结果
- All-cause mortality RR 0.99 (0.92-1.06); CV mortality 0.99 (0.90-1.09).
- 方法学质量
- high
- 相关性
- direct
- 局限
- Trials to 2013; few late-stage high-dose users.
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858 随机对照试验全文，含结构化偏倚风险评估ORIGIN RCT.
- 实际结果
- All-cause death HR 0.98 (0.90-1.08); cancer HR 1.00.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Early dysglycaemia.
UKPDS legacy: 10 years after the trial
UKPDS long-term follow-up.
- 实际结果
- Death -13%.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Newly diagnosed.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Randomised evidence shows no mortality increase with insulin in T2D; the observational associations are explained largely by confounding by indication and reverse causation.
为什么有些研究权重更大
RCT meta-analysis directly excludes a doubling; retrospective database studies are at critical risk of bias.
因果关系是否已确立？ 尚未确立 No randomised evidence of harm; observational signals confounded.
仍存在的不确定性
Late-stage, high-dose, very insulin-resistant patients are under-represented in RCTs.
合理的结论
Mostly false.
为什么研究结果看起来互相矛盾？
Observational cohorts (higher mortality) vs RCTs (neutral): different patient mix (insulin given to sicker patients) and analytic biases explain the discrepancy.
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Is a doubling of mortality compatible with RCT CIs? – No: all-cause RR 0.99 (0.92-1.06); RR 2.0 lies far outside 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- All-cause mortality with insulin therapy in T2D
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (few late-stage, high-dose patients in RCTs)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"insulin") AND (TITLE:"mortality") AND "type 2 diabetes" AND (cohort OR observational) AND PUB_YEAR:[2016 TO 2026] | 支持性证据 | 94 | |
| PubMed | 2026年10月26日 | (insulin[ti]) AND ("all-cause mortality" OR "mortality") AND "type 2 diabetes" AND (dose OR "IU/kg") AND (cohort OR "observational") | 支持性证据 | 32 | |
| PubMed | 2026年10月26日 | "confounding by indication" AND insulin AND mortality AND "type 2 diabetes" | 反对性证据 | 5 | |
| PubMed | 2026年10月26日 | Erpeldinger S[au] AND insulin | 反对性证据 | 2 | |
| PubMed | 2026年10月26日 | (insulin therapy OR "insulin treatment") AND "type 2 diabetes" AND (cardiovascular OR mortality) AND meta-analysis[pt] AND (randomized OR randomised) | 反对性证据 | 210 |
核查深度如何？
12 项相关研究：4 项核查了全文（其中 4 项进行了结构化偏倚风险评估），8 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Verdict unchanged. Certainty raised from low to moderate because an RCT meta-analysis (20 trials, 18,599 patients) directly tests the mortality question and excludes a doubling (RR 0.99, 0.92-1.06); the remaining indirectness concerns late-stage, high-dose users.
新来源: I-INS-122
通俗解释
几项大型数据库研究发现，使用胰岛素的2型糖尿病患者比使用口服药的人死得更早、患癌更多。但胰岛素使用者通常病情更重、患糖尿病的时间更长，所以这种比较是不公平的。当胰岛素在随机对照试验中接受公平的检验时，它并没有增加死亡、心脏病或癌症。这些研究的作者自己也表示，他们的结果不能证明存在因果关系。
与该说法相关的研究
支持该说法的研究 (6)
-
UK database: insulin users vs metformin users
Currie CJ et al.. J Clin Endocrinol Metab 2013 · PMID 23372169 · DOI 10.1210/jc.2012-3042队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究People treated with insulin alone had about twice the death rate of metformin users, but they were also sicker.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 极低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Risk of adverse events with five glucose-lowering regimens
- 研究是如何开展的？
Retrospective cohort, UK General Practice Research Database
- 研究了多少人、动物或样本？
84,622 patients; 105,123 exposure periods; Primary care type 2 diabetes
- 实际发现了什么？
Insulin monotherapy associated with higher risks of death, MACE, cancer, complications.
- 观察到的效应有多大？
aHR 2.197 death
- 研究结果对日常生活意味着什么？
Shows insulin users fare worse, not that insulin causes it.
- 该研究有哪些局限？
Insulin users had longer diabetes (5.2 vs 1.5 years), more kidney and heart disease; ~3 years follow-up; censoring at treatment switch; authors note confounding by indication; authors have industry ties.
- 它对 Elawady 的具体说法说明了什么？
Main observational support for C-INS-05.
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
That insulin causes death, cancer or kidney failure; any insulin dose-response.
-
Long-term sugar level and survival in type 2 diabetes
Currie CJ et al.. Lancet 2010 · PMID 20110121 · DOI 10.1016/S0140-6736(09)61969-3队列研究被 Tayebat 档案网站引用已核查摘要Both very low (6.4%) and very high (10.5%) HbA1c were linked to more deaths; lowest risk around 7.5%.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Survival as a function of HbA1c
- 研究是如何开展的？
Retrospective cohort (GPRD)
- 研究了多少人、动物或样本？
47,970 (27,965 + 20,005); Type 2 diabetes >=50 years intensified to combination orals or insulin
- 实际发现了什么？
U-shaped mortality curve.
- 观察到的效应有多大？
HR 1.52 low; 1.79 high
- 研究结果对日常生活意味着什么？
Moderate control is associated with best survival; high sugar is also harmful.
- 该研究有哪些局限？
Observational; Confounding by indication; Industry funding
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
Causality.
-
Higher insulin doses and outcomes
Holden SE et al.. Diabetes Obes Metab 2015 · PMID 25399739 · DOI 10.1111/dom.12412队列研究被 Tayebat 档案网站引用已核查摘要★ 关键研究People on higher insulin doses died more often, but higher doses are needed by sicker, more insulin-resistant people.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Association of insulin dose with mortality, MACE, cancer
- 研究是如何开展的？
Retrospective cohort, UK CPRD, time-dependent dose exposure
- 研究了多少人、动物或样本？
6,484; Type 2 diabetes progressing to insulin monotherapy from 2000
- 实际发现了什么？
Dose-associated increases in death, MACE, cancer.
- 观察到的效应有多大？
aHR 1.54 per IU/kg/day
- 研究结果对日常生活意味着什么？
High doses mark severe disease; cause unclear.
- 该研究有哪些局限？
Dose reflects insulin resistance and illness; Reverse causation; Residual confounding
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
That lowering doses would save lives.
-
Diabetes drugs and cancer deaths in Canada
Bowker SL et al.. Diabetes Care 2006 · PMID 16443869 · DOI 10.2337/diacare.29.02.06.dc05-1558队列研究被 Tayebat 档案网站引用已核查摘要Insulin users had more cancer deaths than metformin users, possibly due to other differences.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Antidiabetic therapy and cancer mortality
- 研究是如何开展的？
Population-based cohort (Saskatchewan Health)
- 研究了多少人、动物或样本？
10,309; New users of metformin or sulfonylureas
- 实际发现了什么？
aHR 1.9 for insulin.
- 观察到的效应有多大？
aHR 1.9 (1.5-2.4)
- 研究结果对日常生活意味着什么？
Association, cause unknown.
- 该研究有哪些局限？
No BMI/smoking; Confounding
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Canadian data.
- 从该研究中明确不能得出什么结论？
Causation.
-
Amount of insulin and cancer deaths
Bowker SL et al.. Diabetologia 2010 · PMID 20407744 · DOI 10.1007/s00125-010-1750-8队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估More insulin prescriptions went with more cancer deaths, which may reflect that very ill people need more insulin.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Glucose-lowering agents and cancer mortality
- 研究是如何开展的？
Population-based cohort with time-varying exposure
- 研究了多少人、动物或样本？
10,309; New users of metformin/SU
- 实际发现了什么？
More insulin dispensations went with more cancer deaths (HR up to 6.40); weaker (HR 2.47) when only new insulin users were compared.
- 观察到的效应有多大？
aHR 6.40 (>=12 dispensations)
- 研究结果对日常生活意味着什么？
Association only.
- 该研究有哪些局限？
No data on BMI, smoking, blood sugar control; insulin 'dose' is the number of pharmacy fills, which rises when people are seriously ill; few deaths.
- 它对 Elawady 的具体说法说明了什么？
Association for C-INS-05.
- 研究结果是否适用于德国和欧洲？
Canadian data.
- 从该研究中明确不能得出什么结论？
Causation.
-
Second drug after metformin: insulin or sulfonylurea
Roumie CL et al.. JAMA 2014 · PMID 24915260 · DOI 10.1001/jama.2014.4312队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Veterans who added insulin died more often than those who added a sulfonylurea, but heart attacks and strokes were not more frequent.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Adding insulin vs sulfonylurea to metformin: AMI, stroke, death
- 研究是如何开展的？
Retrospective cohort with propensity matching and marginal structural models (VHA, Medicare, NDI)
- 研究了多少人、动物或样本？
178,341 (matched 2,436 insulin vs 12,180 SU); Veterans initially treated with metformin
- 实际发现了什么？
Composite aHR 1.30; death aHR 1.44; CV events not increased.
- 观察到的效应有多大？
aHR 1.30 (1.07-1.58)
- 研究结果对日常生活意味着什么？
Possibly reflects sicker patients getting insulin.
- 该研究有哪些局限？
Residual confounding (sicker patients get insulin); median follow-up about 1 year; mostly male veterans; extra deaths were mainly from cancer and other non-heart causes.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
US veterans.
- 从该研究中明确不能得出什么结论？
That insulin causes death.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (5)
-
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Over six years insulin did not change heart attacks, strokes or cancers, but caused more low-sugar episodes and 2 kg weight difference.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
- 研究是如何开展的？
International multicentre RCT, 2x2 factorial (ORIGIN)
- 研究了多少人、动物或样本？
12,537; CV risk factors plus IFG, IGT or type 2 diabetes; mean age 63.5
- 实际发现了什么？
Neutral CV and cancer outcomes; more hypoglycaemia, slight weight gain.
- 观察到的效应有多大？
HR 1.02 CV; HR 1.00 cancer
- 研究结果对日常生活意味着什么？
Insulin itself did not cause heart disease or cancer in this large trial.
- 该研究有哪些局限？
Open-label; funded by the glargine manufacturer; early-diabetes population on moderate doses (~28 units/day for 70 kg).
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
Safety in very high-dose, late-stage type 2 diabetes.
-
Glargine and cancer in a randomised trial
Bordeleau L et al.. Diabetes Care 2014 · PMID 24574355 · DOI 10.2337/dc13-1468随机对照试验独立交叉核查已核查摘要★ 关键研究Cancer rates were identical with glargine and standard care (1.32 per 100 person-years each).
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Effect of glargine and n-3 fatty acids on incident cancers
- 研究是如何开展的？
Cancer substudy of the ORIGIN 2x2 factorial RCT
- 研究了多少人、动物或样本？
12,537 (953 cancer events); Dysglycaemia with high CV risk, mean age 63.5
- 实际发现了什么？
No difference in any cancer outcome.
- 观察到的效应有多大？
1.32 vs 1.32 per 100 PY
- 研究结果对日常生活意味着什么？
Glargine does not increase cancer within 6 years.
- 该研究有哪些局限？
Industry funding; 6 years may be short for some cancers
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
- 从该研究中明确不能得出什么结论？
Effects after many decades.
-
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS Group. Lancet 1998 · PMID 9742976随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intensive control with sulfonylurea or insulin vs diet on complications
- 研究是如何开展的？
Multicentre RCT (UKPDS 33)
- 研究了多少人、动物或样本？
3,867; Newly diagnosed type 2 diabetes, median age 54
- 实际发现了什么？
Microvascular -25%; more hypoglycaemia and weight gain with insulin.
- 观察到的效应有多大？
RR reduction 25% microvascular
- 研究结果对日常生活意味着什么？
Insulin helps prevent complications but has side effects.
- 该研究有哪些局限？
Open-label; Older drug regimens
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
That insulin is harmful overall.
-
UKPDS legacy: 10 years after the trial
Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470随机对照试验独立交叉核查已核查摘要★ 关键研究People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Do UKPDS benefits persist and do macrovascular effects emerge?
- 研究是如何开展的？
Post-trial monitoring of an RCT (UKPDS 80)
- 研究了多少人、动物或样本？
4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS
- 实际发现了什么？
Legacy reductions in MI and death.
- 观察到的效应有多大？
Death -13% (SU/insulin), -27% (metformin)
- 研究结果对日常生活意味着什么？
Early good control pays off for decades.
- 该研究有哪些局限？
Post-trial therapy not controlled; Questionnaire follow-up
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
Effects of extreme targets in late disease.
-
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-zMeta分析独立交叉核查已核查摘要★ 关键研究In 20 trials with 18,599 people, insulin did not change the risk of death but caused more severe low blood sugar.
RCT mortality RR 0.99 (0.92-1.06) excludes a doubling.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise RCTs of insulin in T2D.
- 研究是如何开展的？
Meta-analysis of 20 RCTs.
- 研究了多少人、动物或样本？
18,599 patients.
- 实际发现了什么？
Mortality unchanged; severe hypoglycaemia +70%.
- 观察到的效应有多大？
RR 0.99 death; 1.70 severe hypoglycaemia.
- 研究结果对日常生活意味着什么？
Insulin does not kill, but low sugar is a real risk; use it carefully.
- 该研究有哪些局限？
Older trials; heterogeneity.
- 它对 Elawady 的具体说法说明了什么？
Refutes 'insulin doubles mortality'; supports caution.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot address insulin in type 1 diabetes, where it is essential.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Adding metformin to insulin
Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133随机对照试验被 Tayebat 档案网站引用已核查摘要Metformin improved sugar control and reduced insulin need and weight gain.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Metformin added to intensive insulin in type 2 diabetes
- 研究是如何开展的？
Double-blind placebo-controlled RCT
- 研究了多少人、动物或样本？
390; Insulin-treated type 2 diabetes
- 实际发现了什么？
Better control, less insulin, less weight gain.
- 观察到的效应有多大？
GHb -0.7%
- 研究结果对日常生活意味着什么？
Combination lowers insulin needs.
- 该研究有哪些局限？
Short duration; Dropouts higher with metformin
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Dutch data.
- 从该研究中明确不能得出什么结论？
That insulin can be stopped.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 在数据库研究中，胰岛素使用者的结局更差，是因为他们病情更重；纳入超过18,000名患者的随机对照试验表明，胰岛素不会增加死亡，尽管它会导致更多的低血糖。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.. Currie CJ et al.. J Clin Endocrinol Metab 2013 · PMID 23372169 · DOI 10.1210/jc.2012-3042
- Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.. Currie CJ et al.. Lancet 2010 · PMID 20110121 · DOI 10.1016/S0140-6736(09)61969-3
- Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.. Holden SE et al.. Diabetes Obes Metab 2015 · PMID 25399739 · DOI 10.1111/dom.12412
- Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.. Bowker SL et al.. Diabetes Care 2006 · PMID 16443869 · DOI 10.2337/diacare.29.02.06.dc05-1558
- Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.. Bowker SL et al.. Diabetologia 2010 · PMID 20407744 · DOI 10.1007/s00125-010-1750-8
- Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.. Roumie CL et al.. JAMA 2014 · PMID 24915260 · DOI 10.1001/jama.2014.4312
- Basal insulin and cardiovascular and other outcomes in dysglycemia.. ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858
- The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.. Bordeleau L et al.. Diabetes Care 2014 · PMID 24574355 · DOI 10.2337/dc13-1468
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
- 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
- Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.. Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z
- Combination of insulin and metformin in the treatment of type 2 diabetes.. Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133